From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer". Prior to 2002 it was described as targeting CD44 v8.
- Postema; et al. (2003). "Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer.".
- Börjesson; et al. (2003). "Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma.".
- WHO Drug Information Vol. 16, No. 3, 2002
- WHO Drug Information, Vol. 15, No. 1, 2001 Recommended INN: List 45. p4
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|